CD274 and neoplasm: In addition, no data on the tumor-infiltrating lymphocytes, programmed death-ligand 1 (PD-L1) expression, and tumor mutational burden are provided here; then again, the approval of pembrolizumab in dMMR tumors does not take into account these features.